Clinical Trial Update: Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients With Psoriasis

View source ↗

Summary

The completed trial assessed how IL-17 and IL-23 inhibitors affect markers of subclinical atherosclerosis in psoriasis patients, reporting results related to ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Psoriasis

Drugs mentioned

• Cosentyx (secukinumab)
• SKYRIZI (risankizumab-rzaa)
• TALTZ (IXEKIZUMAB)
• TREMFYA (guselkumab)

Snippet

Sponsor: National and Kapodistrian University of Athens | Conditions: Psoriasis, Cardiovascular Disease | Status: COMPLETED